[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Spyre Therapeutics Inc (SYRE)

Spyre Therapeutics Inc (SYRE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,488,881
  • Shares Outstanding, K 78,784
  • Annual Sales, $ 0 K
  • Annual Income, $ -155,200 K
  • EBIT $ -210 M
  • EBITDA $ -221 M
  • 60-Month Beta 2.93
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 10.12

Options Overview Details

View History
  • Implied Volatility 78.20% (+1.82%)
  • Historical Volatility 84.00%
  • IV Percentile 9%
  • IV Rank 11.21%
  • IV High 222.63% on 09/16/25
  • IV Low 59.96% on 08/18/25
  • Expected Move (DTE 20) 11.48 (16.47%)
  • Put/Call Vol Ratio 0.10
  • Today's Volume 23
  • Volume Avg (30-Day) 526
  • Put/Call OI Ratio 0.48
  • Today's Open Interest 8,871
  • Open Int (30-Day) 5,147
  • Expected Range 58.20 to 81.15

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.66
  • Number of Estimates 6
  • High Estimate $-0.59
  • Low Estimate $-0.76
  • Prior Year $-0.74
  • Growth Rate Est. (year over year) +10.81%

Price Performance

See More
Period Period Low Period High Performance
1-Month
42.68 +63.24%
on 03/25/26
75.00 -7.11%
on 04/13/26
+27.45 (+65.02%)
since 03/24/26
3-Month
30.92 +125.32%
on 02/04/26
75.00 -7.11%
on 04/13/26
+37.63 (+117.48%)
since 01/23/26
52-Week
12.28 +467.11%
on 05/08/25
75.00 -7.11%
on 04/13/26
+54.74 (+366.64%)
since 04/24/25

Most Recent Stories

More News
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million

WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies...

SYRE : 69.67 (+0.62%)
Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock

WALTHAM, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody...

SYRE : 69.67 (+0.62%)
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock

WALTHAM, Mass., April 13, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody...

SYRE : 69.67 (+0.62%)
Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients

SPY001 met its primary endpoint with a  statistically significant reduction of 9.2 points (p

SYRE : 69.67 (+0.62%)
Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026

WALTHAM, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine...

SYRE : 69.67 (+0.62%)
Spyre Therapeutics Announces Grants of Inducement Awards

WALTHAM, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies...

SYRE : 69.67 (+0.62%)
Spyre Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Q3 2026

Recruitment for the rheumatoid arthritis (RA) sub-study of the SKYWAY basket trial is complete; Week 12 topline data now expected in Q3 2026 Recruitment for the psoriatic arthritis (PsA) and axial...

SYRE : 69.67 (+0.62%)
Spyre Therapeutics Announces Grants of Inducement Awards

WALTHAM, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies...

SYRE : 69.67 (+0.62%)
Spyre Therapeutics to Participate in Upcoming March Investor Conferences

WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine...

SYRE : 69.67 (+0.62%)
Spyre Therapeutics: Q4 Earnings Snapshot

Spyre Therapeutics: Q4 Earnings Snapshot

SYRE : 69.67 (+0.62%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Spyre Therapeutics is a biotechnology company which aims to create inflammatory bowel disease products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches for patient selection. Spyre Therapeutics, formerly known as Aeglea BioTherapeutics Inc., is based...

See More

Key Turning Points

3rd Resistance Point 75.32
2nd Resistance Point 73.70
1st Resistance Point 71.68
Last Price 69.67
1st Support Level 68.04
2nd Support Level 66.42
3rd Support Level 64.41

See More

52-Week High 75.00
Last Price 69.67
Fibonacci 61.8% 51.04
Fibonacci 50% 43.64
Fibonacci 38.2% 36.24
52-Week Low 12.28

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.